DNA Damage Measured by the Comet Assay in Head and Neck Cancer Patients Treated with Tirapazamine

Neoplasia

Volumn 1, Issue 5, 1999, Pages 461-467

  Dorie, Mary Jo ^a   Kovacs, Mary S ^a   Gabalski, Edward C ^a   Adam, Markus ^a   Le, Quynh T ^a   Bloch, Daniel A ^a   Pinto, Harlan A ^a   Terris, David J ^a   Brown, J Martin ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comet assay; Eppendorf; Hypoxia; Radiotherapy; Tirapazamine

Indexed keywords

ANTINEOPLASTIC AGENT; OXYGEN; TIRAPAZAMINE; TRIAZINE DERIVATIVE;

ANIMAL; ARTICLE; C3H MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CLINICAL TRIAL; COMET ASSAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; GENETICS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED C3H; MICE, SCID; NEOPLASM TRANSPLANTATION; OXYGEN; TIME FACTORS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0033222410     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900060     Document Type: Article

References (41)

1. Brown JM (1993). SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67, 1163-1170.
2. Moulder JE, and Rockwell S (1984). Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10, 695-712.
3. Vaupel PW, and Hockel M (1995). Oxygenation status of human tumors: a reappraisal using computerized pO2 histography. In Tumor Oxygenation. Vaupel PW, Kelleher DK and Gunderoth M (Eds.). Gustav Fischer Verlag, Stuttgart, pp. 219-232.
4. Dorie MJ, and Brown JM (1993). Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53, 4633-4636.
5. Kovacs MS, Hocking DJ, Evans JW, Siim BG, Wouters BG, and Brown JM (1999). Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin [ In Process Citation]. Br J Cancer 80, 1245-1251.
6. von Pawet J, and von Roemeling R (1998). Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT 1 trial. Proc Amer Soc Clin Oncol 17, 454a Abstr #1749.
7. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, and Lee WW (1986). SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells, Int J Radiat Oncol Biol Phys 12, 1239-1242.
8. Kim IH, and Brown JM (1994). Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 29, 493-497.
9. Durand RE, and Olive PL (1997). Physiological and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Invest 5, 213-219.
10. Gray LH, Conger AD, Ebert M, Hornsey S, and Scott OC (1953). Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Brit J Radiol 26, 638-648.
11. Gatenby RA, Kessler HB, Rosenblum JS, Cola LR, Moldofsky PJ, and Hartz WH (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14, 831-838.
12. Nordsmark M, Overgaard M, and Overgaard J (1996). Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41, 31-40.
13. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, and Dewhirst MW (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38, 285-289.
14. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, and Vaupel P (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56, 4509-4515.
15. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, and Dewhirst MW (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56, 941-943.
16. Brown JM, and Lemmon MJ (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50, 7745-7749.
17. Brown JM, and Lemmon MJ (1991). Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20, 457-461.
18. Lee D-J, Trotti ASS, Rostock R, Fisher C, von Roemeling R, Harvey E, and Groves E (1998). Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 42, 811-815.
19. Siim BG, van Zijl PL, and Brown JM (1996). Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity toward hypoxic tumour cells in vitro. Br J Cancer 73, 952-960.
20. Olive PL, Vikse CM, and Banath JP (1996). Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice. Cancer Res 56, 4460-4463.
21. Siim BG, Menke DR, Dorie MJ, and Brown JM (1997). Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 57, 2922-2928.
22. Adam MF, Dorie MJ, and Brown JM (1999). Oxygen tension measurements of tumors growing in mice. Int J Rad Oncol Biol Phys 45, 171-180.
23. Terris DJ, and Dunphy EP (1994). Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg 120, 283-287.
24. Adam M, Gabalski EC, Bloch DA, Oehlert JW, Brown JM, Elsaid AA, Pinto HA, and Terris DJ (1999). Tissue oxygen distribution in head and neck cancer patients. Head and Neck 21, 146-153.
25. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, and Kallman RF (1980). A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 64, 595-604.
26. Hirst DG, Brown JM, and Hazlehurst JL (1983). Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res 43, 1961-1965.
27. Olive PL, Wlodek D, Durand RE, and Banath JP (1992). Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp Cell Res 198, 259-267.
28. Olive PL, Banath JP, and Durand RE (1990). Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 122, 86-94.
29. Brown JM, and Wang LH (1998). Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des 13, 529-539.
30. Koch CJ (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53, 3992-3997.
31. Brown JM, and Lemmon MJ (1991). SR 4233: A tumor specific radiosensitizer active in fractionated radiation regimes. Radiother. Oncol 20, 151-156.
32. Brown JM, and Koong A (1991). Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst 83, 178-185.
33. Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, and Workman P (1997). Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose escalation strategy in a phase I trial. Cancer Chemother Pharmacokinetics 40, 1-10.
34. Evans JE, Yudoh K, Delahoussaye YM, and Brown JM (1998). Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res 58, 2098-2101.
35. Nordsmark M, Bentzen SM, and Overgaard J (1994). Measurement of human tumour oxygenation status by a polarographic needle electrode. Acta Oncol 33, 383-389.
36. Lartigau E, Le Ridant A-M, Lambin P, Weeger P, Martin L, Sigal R, Lusinchi A, Luboinski B, Eschwege F, and Guichard M (1993). Oxygenation of head and neck tumors. Cancer 71, 2319-2325.
37. Wouters BG, and Brown JM (1997). Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147, 541-550.
38. Kovacs MS, Yudoh K, Evans JW, Menke D, and Brown JM (1997). Stable translocations detected by fluorescence in situ hybridization: a rapid surrogate end point to evaluate the efficacy of a potentiator of tumor response to radiotherapy. Cancer Res 57, 672-677.
39. Olive PL, Banath JP, and Durand RE (1990). Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J Natl Cancer Inst 82, 779-783.
40. Pfuhler S, and Wolf HU (1996). Detection of DNA-crosslinking agents with the alkaline comet assay. Environ Mol Mutagen 27, 196-201.
41. Strauss GH, Peters WP, and Everson RB (1994). Measuring DNA damage in individual cells of heterogeneous mixtures: a novel application of an immunological typing technique. Mutat Res 304, 211-216.